Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18210781 | 1.00 | EGFR (0.48) | EGFRMAOBPARP10KDM4EHPGD | |
| SCHEMBL8171032 | 0.98 | EGFR (0.49) | EGFRMAOBPARP10KDM4EHPGD | |
| SCHEMBL8256707 | 0.93 | PARP10 (0.53) | EGFRMAOBPARP10KDM4EALDH1A1 | |
| SCHEMBL470126 | 0.89 | ACHE (0.46) | EGFRMAOBPARP10ALDH1A1MEN1 | |
| SCHEMBL2242868 | 0.89 | PARP10 (0.55) | PARP10HPGDALDH1A1TSHRGRM2 | |
| SCHEMBL18175567 | 0.88 | EGFR (0.41) | EGFRMAOBPARP10KDM4EHPGD | |
| SCHEMBL12431902 | 0.83 | MAOB (0.52) | MAOBHRH3 | |
| SCHEMBL3148517 | 0.83 | MAPT (0.51) | PARP10KDM4EHPGDALDH1A1TSHR | |
| SCHEMBL21118539 | 0.81 | EGFR (0.46) | EGFRMAOBMEN1KMT2AGRM2 | |
| SCHEMBL12807880 | 0.81 | FPR2 (0.40) | EGFRMAOBPARP10ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2020147740-A1 | TRIAZOLE COMPOUNDS, AND PREPARATION METHOD THEREOF AND USE | 武汉朗来科技发展有限公司 | 2020-07-23 | — | — | WO | disclosed |
| WO-2017160861-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-2675274-B1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2356517-B1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORP (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| EP-2399585-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-0547317-A1 | Endothelin antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| EP-0370343-B1 | METHOD FOR THE PRODUCTION OF 4-METHYL-2-CYCLOHEXYLPHENOL | BAYER AG (DE) | 1993-02-03 | — | — | EP | disclosed |
| EP-0499266-A1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-19 | — | — | EP | disclosed |
| EP-0470256-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1992-02-12 | — | — | EP | disclosed |
| WO-1991013089-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-05 | — | — | WO | disclosed |
| US-4990687-A | Preparation of 4-methyl-2-cyclohexylphenol | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
| EP-0370343-A1 | Method for the production of 4-methyl-2-cyclohexylphenol | BAYER AG (DE) | 1990-05-30 | — | — | EP | disclosed |
| US-4849550-A | Method for producing cycloalkanols | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-07-18 | — | — | US | disclosed |
| EP-0285912-A2 | A method for producing cycloalkanols | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-10-12 | — | — | EP | disclosed |
| US-4113782-A | CATALYTIC OXIDATION | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | EGFR 2814/4885MAOB 412/4885PARP10 1539/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | EGFR 1578/4885MAOB 1234/4885PARP10 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.